- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00228917
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children
17 februari 2020 uppdaterad av: GlaxoSmithKline
Assess Reactogenicity & Safety of a Booster of Either Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix Given (Single-blind) at 15-18 (Philippines)/15-24 Mths (Thailand) & a Dose of Mencevax ACWY at 24-30 Mths (Open Label)
This study will be conducted in two stages.
In the diphtheria, tetanus, pertussis (DTP) booster phase, subjects will receive a booster dose of Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix (active control) at 15 to 18 or 24 months in a single-blind manner so that the subjects' parents will not know which vaccine was administered to their child.
In the Mencevax ACWY phase at 24-30 months, a dose of Mencevax ACWY will be given in an open manner to only those subjects who received less than 4 doses of Tritanrix-HepB/Hib-MenAC.
No blood samples will be taken in this safety study.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Subjects previously primed with Tritanrix-HepB/Hib-MenAC will receive Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix vaccine (at 15-18/24 m), respectively, without or with Mencevax ACWY vaccine at 24 to 30 months of age.
Subjects previously primed with Tritanrix-HepB/Hiberix will receive Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix vaccine (at 15-18/24 m) with Mencevax ACWY vaccine at 24 to 30 months of age.
Studietyp
Interventionell
Inskrivning (Faktisk)
798
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Muntinlupa, Filippinerna, 1781
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10400
- GSK Investigational Site
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
1 år till 1 år (Barn)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Written informed consent obtained from the parent or guardian of a healthy male or female child between, and including 15 and 18 months age (Philippines)/ 15 and 24 months age (Thailand) at the time of vaccination and who have previously received a 3-dose primary vaccination in the studies DTPwHB/HibMenAC-TT-004 (CPMS No. 759346/004) or DTPW-HBV=HIB-MENAC-TT-013 (eTrack No. 100791).
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the vaccination, or planned use during the study period.
- Chronic administration (> than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to vaccination.
- Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of vaccination. Note: Oral poliovirus vaccine can be given concomitantly.
- Booster vaccination against diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b (Hib) and/or meningococcal serogroups A and C disease, after the date of the study conclusion visit of the primary vaccination study.
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: ACAC_Thailand Group
Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study ( NCT00317187) are boosted in the current study with one dose of the same vaccines at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
No Mencevax ACWY vaccine at 24 to 30 months of age
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B, Haemophilus influenzae Typ b meningokock AC-stelkrampstoxoid konjugatvaccin
|
Experimentell: ACHibPS_Thailand Group
Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B-vaccin, Haemophilus influenzae typ b konjugatvaccin
Meningococcal Serogroups A, C, W-135 and Y Vaccine
|
Experimentell: HibACPS_Thailand Group
Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B, Haemophilus influenzae Typ b meningokock AC-stelkrampstoxoid konjugatvaccin
Meningococcal Serogroups A, C, W-135 and Y Vaccine
|
Experimentell: HibHibPS_Thailand Group
Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317187) are boosted in the current study with one dose of the same vaccine at 15 to 24 months (Thailand) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B-vaccin, Haemophilus influenzae typ b konjugatvaccin
Meningococcal Serogroups A, C, W-135 and Y Vaccine
|
Experimentell: ACAC_Philippines Group
Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccines at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
No Mencevax ACWY vaccine at 24 to 30 months of age
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B, Haemophilus influenzae Typ b meningokock AC-stelkrampstoxoid konjugatvaccin
|
Experimentell: ACHibPS_Philippines Group
Subjects vaccinated with 3 doses of Tritanrix-Hepb co-administrated with Hib-MenAC-TT vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Tritanrix-HepB/Hiberix at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B-vaccin, Haemophilus influenzae typ b konjugatvaccin
Meningococcal Serogroups A, C, W-135 and Y Vaccine
|
Experimentell: HibACPS_Philippines Group
Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of Trianrix-Hepb co-administrated with Hib-MenAC-TT vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B, Haemophilus influenzae Typ b meningokock AC-stelkrampstoxoid konjugatvaccin
Meningococcal Serogroups A, C, W-135 and Y Vaccine
|
Experimentell: HibHibPS_Philippines Group
Subjects vaccinated with 3 doses of Tritanrix-HepB/Hiberix vaccine in the primary study (NCT00317135) are boosted in the current study with one dose of the same vaccine at 15 to 18 months (Philippines) of age, intramuscularly into the anterolateral quadrant of the left thigh or upper region of the left arm.
Subjects are also administered one booster dose of Mencevax ACWY vaccine at 24 to 30 months of age by deep subcutaneous injection in the upper region of the left arm
|
Kombinerad difteri, stelkramp, helcellskikhosta, hepatit B-vaccin, Haemophilus influenzae typ b konjugatvaccin
Meningococcal Serogroups A, C, W-135 and Y Vaccine
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Subjects With Fever >39°C (Rectal Route).
Tidsram: During the 4-day (Day 0-3) follow-up period after booster vaccination
|
Among solicited general symptoms fever [defined as rectal temperature equal to or above (≥) 38 degrees Celsius (°C )] was assessed, post vaccination.
Grade 3 fever = fever > 39.0 °C.
|
During the 4-day (Day 0-3) follow-up period after booster vaccination
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms, Other Than Fever > 39.0°C
Tidsram: During the 4-day (Day 0-3) follow-up period after vaccination
|
Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above 38 degrees Celsius (°C)].
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 symptom = symptom that prevented normal activity.
Related = symptom assessed by the investigator as related to the vaccination.
|
During the 4-day (Day 0-3) follow-up period after vaccination
|
Number of Subjects With Any and Grade 3 Solicited Local Symptoms.
Tidsram: During the 4-day (Day 0-3) follow-up period after booster vaccination
|
Assessed solicited local symptoms were pain, redness and swelling.
Any = occurrence of the symptom regardless of intensity grade.
Grade 3 pain = pain that prevented normal activity.
Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimeters (mm) of injection site.
|
During the 4-day (Day 0-3) follow-up period after booster vaccination
|
Number of Subjects With Any Unsolicited Adverse Events (AEs).
Tidsram: During the 31-day (Day 0-30) following booster vaccination
|
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
|
During the 31-day (Day 0-30) following booster vaccination
|
Number of Subjects With Serious Adverse Events (SAEs).
Tidsram: From 15 to 18 months or 15 to 24 months of age and up to 25 to 31 months of age post vaccination
|
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
|
From 15 to 18 months or 15 to 24 months of age and up to 25 to 31 months of age post vaccination
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
16 juni 2005
Primärt slutförande (Faktisk)
20 januari 2006
Avslutad studie (Faktisk)
20 januari 2006
Studieregistreringsdatum
Först inskickad
27 september 2005
Först inskickad som uppfyllde QC-kriterierna
27 september 2005
Första postat (Uppskatta)
29 september 2005
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
20 februari 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
17 februari 2020
Senast verifierad
1 februari 2020
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Matsmältningssystemets sjukdomar
- Metaboliska sjukdomar
- Sjukdomar i nervsystemet
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Luftvägsinfektioner
- Luftvägssjukdomar
- Blodburna infektioner
- Smittsamma sjukdomar
- Neurologiska manifestationer
- Leversjukdomar
- Hepatit, Viral, Human
- Hepadnaviridae-infektioner
- DNA-virusinfektioner
- Bordetella infektioner
- Gram-negativa bakteriella infektioner
- Bakteriella infektioner
- Bakteriella infektioner och mykoser
- Gram-positiva bakteriella infektioner
- Neuromuskulära manifestationer
- Actinomycetales infektioner
- Enterovirusinfektioner
- Picornaviridae-infektioner
- Orthomyxoviridae-infektioner
- Clostridium infektioner
- Hypokalcemi
- Kalciummetabolismstörningar
- Corynebacterium-infektioner
- Hepatit B
- Kikhosta
- Hepatit
- Hepatit A
- Influensa, människa
- Stelkramp
- Difteri
- Tetany
Andra studie-ID-nummer
- 103812
- 104171 (Annan identifierare: GSK)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Ja
IPD-planbeskrivning
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Studiedata/dokument
-
Statistisk analysplan
Informationsidentifierare: 103812Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättning för individuella deltagare
Informationsidentifierare: 103812Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register. The results of this study 103812 are summarised with study 104727 on the GSK Clinical Study Register.
-
Informerat samtycke
Informationsidentifierare: 103812Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokoll
Informationsidentifierare: 103812Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datauppsättningsspecifikation
Informationsidentifierare: 103812Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk studierapport
Informationsidentifierare: 103812Informationskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Hepatit B
-
Nathan DenlingerBristol-Myers SquibbRekryteringB-cells non-Hodgkin lymfom - återkommande | Diffust stort B-cellslymfom - återkommande | Follikulärt lymfom - återkommande | Höggradigt B-cellslymfom - återkommande | Primärt mediastinalt stort B-cellslymfom - återkommande | Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort... och andra villkorFörenta staterna
-
Northwestern UniversityNational Cancer Institute (NCI)Aktiv, inte rekryterandeDiffust stort B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Höggradigt B-cellslymfom, ej specificerat på annat sätt | T-cell/Histiocyt-rik stort B-cellslymfom | Höggradigt B-cellslymfom med MYC och BCL2 och/eller BCL6 omarrangemang | Diffust stort B-cellslymfom aktiverat... och andra villkorFörenta staterna
-
Nanfang Hospital of Southern Medical UniversityRekryteringB-cellslymfom | B-cells akut lymfoblastisk leukemi | B-cellsleukemi | B-cellslymfom refraktär | B-cellslymfom ÅterkommandeKina
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom aktiverat B-cellstyp | Refraktärt diffust stort B-cellslymfom aktiverat B-cellstypFörenta staterna, Saudiarabien
-
Lapo AlinariRekryteringÅterkommande höggradigt B-cellslymfom med MYC, BCL2 och BCL6 omarrangemang | Refraktärt höggradigt B-cellslymfom med MYC, BCL2 och BCL6 omarrangemang | Återkommande höggradigt B-cellslymfom med MYC och BCL2 eller BCL6 omarrangemang | Refraktärt höggradigt B-cellslymfom med MYC och BCL2 eller... och andra villkorFörenta staterna
-
Athenex, Inc.RekryteringB-cells lymfom | CLL/SLL | ALLA, barndom | DLBCL - Diffust stort B-cellslymfom | B-cell leukemi | NHL, Återfall, Vuxen | ALL, vuxen B-cellFörenta staterna
-
Ohio State University Comprehensive Cancer CenterRekryteringDiffust stort B-cellslymfom | Höggradigt B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Diffust stort B-cellslymfom Germinalt centrum B-cellstypFörenta staterna
-
Curocell Inc.RekryteringHöggradigt B-cellslymfom | Diffust stort B-cellslymfom (DLBCL) | Primärt mediastinalt stort B-cellslymfom (PMBCL) | Transformerat follikulärt lymfom (TFL) | Refraktärt stort B-cellslymfom | Återfall av stort B-cellslymfomKorea, Republiken av
-
National Cancer Institute (NCI)RekryteringHöggradigt B-cellslymfom | Diffust stort B-cellslymfom, ej specificerat på annat sätt | Transformerat indolent B-cells non-Hodgkin-lymfom till diffust stort B-cellslymfomFörenta staterna
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenAktiv, inte rekryterandeÅterkommande diffust stort B-cellslymfom | Refraktärt diffust stort B-cellslymfom | CD20 positiv | Steg I diffust stort B-cellslymfom | Steg II diffust stort B-cellslymfom | Steg III Diffust stort B-cellslymfom | Steg IV Diffust stort B-cellslymfomFörenta staterna
Kliniska prövningar på Tritanrix-HepB/Hib-MenAC
-
GlaxoSmithKlineAvslutadHepatit B | Stelkramp | Difteri | Haemophilus Influenzae Typ b | Helcellskikhosta | Difteri-stelkramp-kikhosta-Hepatit B-Haemophilus Influenzae Typ b-Neisseria Meningitidis-vaccinThailand
-
GlaxoSmithKlineAvslutadHepatit B | Stelkramp | Difteri | Haemophilus Influenzae Typ b | HelcellskikhostaFilippinerna
-
GlaxoSmithKlineAvslutadHepatit B | Stelkramp | Difteri | Haemophilus Influenzae Typ b | HelcellskikhostaThailand
-
GlaxoSmithKlineAvslutadHepatit B | Stelkramp | Difteri | Haemophilus Influenzae Typ b | HelcellskikhostaFilippinerna
-
GlaxoSmithKlineAvslutadInfektioner, streptokockerBurkina Faso
-
GlaxoSmithKlineAvslutadHepatit B | Stelkramp | Difteri | Haemophilus Influenzae Typ b | HelcellskikhostaIndien
-
Sanofi Pasteur, a Sanofi CompanyAvslutadHepatit B | Kikhosta | Stelkramp | Difteri | Haemophilus Influenzae Typ bPeru, Mexiko
-
GlaxoSmithKlineAvslutadHepatit B | Stelkramp | Difteri | Haemophilus Influenzae Typ b | HelcellskikhostaArgentina, Nicaragua
-
GlaxoSmithKlineAvslutad
-
Sanofi Pasteur, a Sanofi CompanyAvslutadHepatit B | Kikhosta | Stelkramp | Difteri | Haemophilus Influenzae Typ bFilippinerna